The role of IL-21 in hematological malignancies

Cytokine

Volumn 56, Issue 2, 2011, Pages 133-139

  Ma, Jingjing ^a   Ma, Daoxin ^a   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Hematological malignancies; IL 21; IL 21R; Immune therapy; JAK STAT signal transduction pathway

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 12; JANUS KINASE; RECOMBINANT INTERLEUKIN 12; STAT PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

APOPTOSIS; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOFLUORESCENCE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOUSE; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TUMOR CELL; WESTERN BLOTTING;

HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKINS; MUTATION;

EID: 80053299704     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.07.011     Document Type: Review

References (56)

1. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin-21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
2. Spolski R., Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008, 26:57-79.
3. Mehta D.S., Wurster A.L., Grusby M.J. Biology of IL-21 and the IL-21 receptor. Immunol Rev 2004, 202:84-95.
4. Ozaki K., Kikly K., Michalovich D., Young P.R., Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 2000, 97:11439-11444.
5. Parrish-Novak J., Foster D.C., Holly R.D., Clegg C.H. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002, 2:856-863.
6. Zeng R., Spolski R., Casas E., Zhu W., Levy D.E., Leonard W.J. The molecular basis of IL-21-mediated proliferation. Blood 2007, 109:4135-4142.
7. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001, 167:1-5.
8. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157. [J Immunol 2008;181:5817-27].
9. Skak K., Kragh M., Hausman D., Smyth M.J., Sivakumar P.V. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008, 7:231-240.
10. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P., et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007, 13:3630-3636.
11. Jahrsdorfer B., Blackwell S.E., Wooldridge J.E., Huang J., Andreski M.W., Jacobus L.S., et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006, 108:2712-2719.
12. Brandt K., Singh P.B., Bulfone-Paus S., Rückert R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev 2007, 18:223-232.
13. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
14. Benekli M., Baumann H., Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 2009, 27:4422-4432.
15. Coffer P.J., Koenderman L., de Groot R.P. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000, 19:2511-2522.
16. Stephanou A., Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 2005, 23:177-182.
17. de Totero D., Meazza R., Zupo S., Cutrona G., Matis S., Colombo M., et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006, 107:3708-3715.
18. Gowda A., Roda J., Hussain S.R., Ramanunni A., Joshi T., Schmidt S., et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008, 111:4723-4730.
19. Lamprecht B., Kreher S., Anagnostopoulos I., Jöhrens K., Monteleone G., Jundt F., et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α. Blood 2008, 112:3339-3347.
20. Jahrsdorfer B., Wooldridge J.E., Blackwell S.E., Taylor C.M., Griffith T.S., Link B.K., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005, 77:378-387.
21. de Totero D., Meazza R., Capaia M., Fabbi M., Azzarone B., Balleari E., et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 2008, 111:517-524.
22. Jin H., Carrio R., Yu A., Malek T.R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004, 173:657-665.
23. Akamatsu N., Yamada Y., Hasegawa H., Makabe K., Asano R., Kumagai I., et al. High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 2007, 256:196-206.
24. Kuchen S., Robbins R., Sims G.P., Sheng C., Phillips T.M., Lipsky P.E., et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol 2007, 179:5886-5896.
25. Good K.L., Bryant V.L., Tangye S.G. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006, 177:5236-5247.
26. Ménoret E., Maïga S., Descamps G., Pellat-Deceunynck C., Fraslon C., Cappellano M., et al. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 2008, 181:6837-6842.
27. Brenne A.T., Ro T.B., Waage A., Sundan A., Borset M., Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002, 99:3756-3762.
28. Diehl S.A., Schmidlin H., Nagasawa M., van Haren S.D., Kwakkenbos M.J., Yasuda E., et al. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol 2008, 180:4805-4815.
29. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
30. Descamps G., Wuillème-Toumi S., Trichet V., Venot C., Debussche L., Hercend T., et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006, 177:4218-4223.
31. Collette M., Descamps G., Pellat-Deceunynck C., Bataille R., Amiot M. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. Eur Cytokine Netw 2007, 18:120-126.
32. Brenne A.T., Fagerli U.M., Shaughnessy J.D., Våtsveen T.K., Rø T.B., Hella H., et al. High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis. Eur J Haematol 2009, 82:354-363.
33. Scheeren F.A., Diehl S.A., Smit L.A., Beaumont T., Naspetti M., Bende R.J., et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111:4706-4715.
34. Caruso R., Fina D., Peluso I., Stolfi C., Fantini M.C., Gioia V., et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007, 132:166-175.
35. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007, 104:13134-13139.
36. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006, 66:5716-5722.
37. de Totero D., Capaia M., Fabbi M., Croce M., Meazza R., Cutrona G., et al. Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol 2010, 38:373-383.
38. Sarosiek K.A., Malumbres R., Nechushtan H., Gentles A.J., Avisar E., Lossos I.S. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 2010, 115:570-580.
39. Akasaka T., Akasaka H., Ueda C., Yonetani N., Maesako Y., Shimizu A., et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin. Oncol 2000, 18:510-518.
40. Gelebart P., Zak Z., Anand M., Dien-Bard J., Amin H.M., Lai R. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009, 23:1836-1846.
41. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750-762.
42. Pimentel-Muinos F.X., Seed B. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999, 11:783-793.
43. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
44. Shishodia S., Amin H.M., Lai R., Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005, 70:700-713.
45. Gill S., Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008, 49:398-409.
46. Ueda M., Imada K., Imura A., Koga H., Hishizawa M., Uchiyama T. Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol 2005, 128:169-176.
47. Takemoto S., Mulloy J.C., Cereseto A., Migone T.S., Patel B.K., Matsuoka M., et al. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA 1997, 94:13897-13902.
48. Amin H.M., Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007, 110:2259-2267.
49. Dien Bard J., Gelebart P., Anand M., Zak Z., Hegazy S.A., Amin H.M., et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 2009, 175:825-834.
50. Amin H.M., Medeiros L.J., Ma Y., Feretzaki M., Das P., Leventaki V., et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22:5399-5407.
51. Amin H.M., McDonnell T.J., Ma Y., Lin Q., Fujio Y., Kunisada K., et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 2004, 23:5426-5434.
52. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629.
53. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
54. Marzec M., Halasa K., Kasprzycka M., Wysocka M., Liu X., Tobias J.W., et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008, 68:1083-1091.
55. Yoon J.S., Newton S.M., Wysocka M., Troxel A.B., Hess S.D., Richardson S.K., et al. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. J Invest Dermatol 2008, 128:473-480.
56. Zhang Q., Wang H.Y., Woetmann A., Raghunath P.N., Odum N., Wasik M.A. STAT3 induces transcription of the DNA methyltransferase 1 (DNMT1) gene in malignant T-lymphocytes. Blood 2006, 108:1058-1064.